For wild-type TP53 AML, researchers have shown that pharmacological autophagy blockade achieves therapeutic benefits, while AMLs harboring TP53 mutations do not respond to the inhibition of autophagy by hydroxychloroquine (HCQ) [153,154]. This evidence concerns the gene TP53 and acute myeloid leukemia.